Show simple item record

dc.contributor.authorSriskandarajah, P
dc.contributor.authorPawlyn, C
dc.contributor.authorMohammed, K
dc.contributor.authorDearden, CE
dc.contributor.authorDavies, FE
dc.contributor.authorMorgan, GJ
dc.contributor.authorBoyd, KD
dc.contributor.authorKaiser, MF
dc.date.accessioned2018-02-16T11:44:11Z
dc.date.issued2017-02
dc.identifier.citationLeukemia & lymphoma, 2017, 58 (2), pp. 494 - 497
dc.identifier.issn1042-8194
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1214
dc.identifier.eissn1029-2403
dc.identifier.doi10.1080/10428194.2016.1198957
dc.formatPrint-Electronic
dc.format.extent494 - 497
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectMultiple Myeloma
dc.subjectRecurrence
dc.subjectThalidomide
dc.subjectAngiogenesis Inhibitors
dc.subjectAntineoplastic Agents
dc.subjectNeoplasm Staging
dc.subjectTreatment Outcome
dc.subjectCombined Modality Therapy
dc.subjectRetreatment
dc.subjectFollow-Up Studies
dc.subjectDrug Resistance, Neoplasm
dc.subjectKaplan-Meier Estimate
dc.subjectNeoplasm Grading
dc.titleThe efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
dc.typeJournal Article
dcterms.dateAccepted2016-06-01
rioxxterms.versionofrecord10.1080/10428194.2016.1198957
rioxxterms.licenseref.startdate2017-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfLeukemia & lymphoma
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Molecular Drug Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Molecular Drug Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume58
pubs.embargo.termsNot known
icr.researchteamMolecular Drug Resistanceen_US
icr.researchteamMyeloma Biology and Therapeuticsen_US
icr.researchteamMyeloma Groupen_US
dc.contributor.icrauthorPawlyn, Charlotteen
dc.contributor.icrauthorSriskandarajah, Priyaen
dc.contributor.icrauthorKaiser, Martinen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record